Table 1. Characteristics of PNH patients... | American Society of Hematology

Table 1.

Characteristics of PNH patients

Patient	Sex	Sampling time point	Age at sampling, y	Time after diagnosis, y	WBC, ×10⁹/L	Hb, g/dL	Platelets, ×10⁹/L	LDH, IU/L*	Treatment at sampling
PNH01	Female	First	44	20	2.4	9.3	101	274	Eculizumab
		Second†	46	22	5.3	9.6	142	192	Eculizumab
PNH02	Female	First	54	28	3.8	11.9	194	195	Eculizumab
		Second‡	57	31	3.3	11.5	119	205	Eculizumab
PNH03	Female	First	83	15	1.6	10.4	107	208	Eculizumab
		Second§	86	18	1.5	9.8	111	215	Eculizumab
PNH04	Female	First	63	3	6.3	7.1	41	168	Cyclosporin A; eculizumab
PNH05	Female	First	49	5	3.7	6.8	180	1898	Metenolone; RBC transfusion
PNH06	Female	First	28	3	5.5	10.6	191	670	Cyclosporin A

Patient	Sex	Sampling time point	Age at sampling, y	Time after diagnosis, y	WBC, ×10⁹/L	Hb, g/dL	Platelets, ×10⁹/L	LDH, IU/L*	Treatment at sampling
PNH01	Female	First	44	20	2.4	9.3	101	274	Eculizumab
		Second†	46	22	5.3	9.6	142	192	Eculizumab
PNH02	Female	First	54	28	3.8	11.9	194	195	Eculizumab
		Second‡	57	31	3.3	11.5	119	205	Eculizumab
PNH03	Female	First	83	15	1.6	10.4	107	208	Eculizumab
		Second§	86	18	1.5	9.8	111	215	Eculizumab
PNH04	Female	First	63	3	6.3	7.1	41	168	Cyclosporin A; eculizumab
PNH05	Female	First	49	5	3.7	6.8	180	1898	Metenolone; RBC transfusion
PNH06	Female	First	28	3	5.5	10.6	191	670	Cyclosporin A

Hb, hemoglobin; LDH, lactate dehydrogenase; RBC, red blood cell; WBC, white blood cell.

Normal range, 110 to 225 IU/L.

After 24 months from first sampling.

After 29 months from first sampling.

After 35 months from first sampling.